Investing where it matters most
We have always viewed R&D as essential to our growth. That is why we are committed to making a significant investment towards it year after year. In fact, over 11% of our employees are engaged full-time in R&D, and a total amount of €106 million was invested in R&D in 2020.
Innovation is at our core
In 2017, we proudly built a new R&D site in the Barcelona area, Spain. This new facility marks the latest chapter in our long history of innovation and we now have nine state-of-the-art R&D and manufacturing facilities - from Europe to North America - that help us maintain our vigorous commitment to progress and advancement around the world.
These facilities are located in Ascoli (Italy), Barcelona (Spain), Bedford, Massachusetts (USA), Munich (Germany), Orangeburg, New York (USA), and San Diego, California (USA).
Decades of innovations
Thanks to our continuous investment in R&D and dedicated specialized teams, we have been at the forefront of decades of landmark discoveries, including the first direct-reading pH/blood gas analyzer and the invention of CO-oximetry, the first fully automated coagulation system, as well as more than 50 biomarkers in the autoimmunity market.
